Successful treatment of breakthrough Trichosporon asahii fungemia with voriconazole in a patient with acute myeloid leukemia

Clin Infect Dis. 2006 Aug 15;43(4):e39-41. doi: 10.1086/505970. Epub 2006 Jun 26.

Abstract

We describe a 55-year-old man with acute myelogenous leukemia who developed breakthrough Trichosporon asahii fungemia during 5 days of micafungin treatment. Although the patient's clinical condition improved considerably after the start of voriconazole treatment, blood culture results remained positive for T. asahii for 3 days, and fever persisted for 7 days thereafter. The patient achieved complete hematological remission, and he received successful consolidation chemotherapy without developing Trichosporon infection with the prophylactic use of voriconazole therapy. This case report illustrates that voriconazole may be useful in the treatment of disseminated T. asahii infection in neutropenic patients.

Publication types

  • Case Reports

MeSH terms

  • Acute Disease
  • Antifungal Agents / therapeutic use*
  • Aspergillosis / complications
  • Aspergillosis / drug therapy
  • Echinocandins
  • Fungemia / drug therapy
  • Humans
  • Leukemia, Myeloid / complications*
  • Lipopeptides
  • Lipoproteins / therapeutic use
  • Male
  • Micafungin
  • Middle Aged
  • Mycoses / complications
  • Mycoses / drug therapy*
  • Mycoses / microbiology
  • Peptides, Cyclic / therapeutic use
  • Pyrimidines / therapeutic use*
  • Triazoles / therapeutic use*
  • Trichosporon / isolation & purification*
  • Voriconazole

Substances

  • Antifungal Agents
  • Echinocandins
  • Lipopeptides
  • Lipoproteins
  • Peptides, Cyclic
  • Pyrimidines
  • Triazoles
  • Voriconazole
  • Micafungin